Your session is about to expire
← Back to Search
Radiation Therapy + Rituximab for Follicular Lymphoma
Phase 1 & 2
Recruiting
Led By Bouthaina S Dabaja
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Newly diagnosed patients with stage I and II follicular lymphoma, pathologically confirmed at MD Anderson Cancer Center (MDACC) to be grade 1 or 2
Be older than 18 years old
Must not have
Patients with pre-existing cardiovascular disease requiring ongoing treatment; this includes: congestive heart failure III/IV as defined by New York Heart Association (NYHA); uncontrolled cardiac arrhythmia; unstable angina pectoris; and recent myocardial infarction (MI) (within 6 months)
Patients who had previous radiation dose to the site of the current primary disease, which would lead to violation of known radiation tolerance limit of that particular site if treated again
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 15 years
Awards & highlights
No Placebo-Only Group
Summary
This trial studies how well radiation therapy and rituximab work in treating patients with early stage follicular lymphoma.
Who is the study for?
This trial is for newly diagnosed patients with early-stage (I-II) grade 1 or 2 follicular lymphoma. Participants must have certain blood cell counts, good performance status, and proper liver and kidney function. Men must use contraception; women must be postmenopausal, surgically sterilized, or using two barrier methods of contraception.
What is being tested?
The study tests the combination of radiation therapy with rituximab against cancer cells in patients with follicular lymphoma. Radiation aims to kill cancer cells directly while rituximab is an antibody that may help the immune system fight cancer.
What are the potential side effects?
Possible side effects include reactions to rituximab like fever and chills, risk of infection due to a weakened immune system, fatigue from radiation therapy, as well as potential damage to nearby organs or tissues.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been newly diagnosed with early-stage follicular lymphoma, confirmed to be grade 1 or 2.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have serious heart problems that need ongoing treatment.
Select...
I've had radiation to the same area where my current cancer is, and can't have more without risking harm.
Select...
I have an active hepatitis B or C infection.
Select...
I am currently using alternative or complementary medicines.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 15 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 15 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Proportion of patients that remain progression free, defined as progressive disease or death due to disease
Secondary study objectives
Overall survival
Progression free survival rate
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Arm II (radiation therapy and observation)Experimental Treatment2 Interventions
Patients undergo radiation therapy five days a week for 2.5 weeks and then undergo observation.
Group II: Arm I (radiation therapy and rituximab)Experimental Treatment2 Interventions
Patients undergo radiation therapy five days a week for 2.5 weeks (12 treatments) and receive rituximab IV over 4-6 hours weekly with the start of radiation for 4 weeks and then every 2 months for up to 4 additional doses in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
1999
Completed Phase 4
~2990
Radiation Therapy
2017
Completed Phase 3
~7250
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,937 Previous Clinical Trials
41,022,353 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
3,069 Previous Clinical Trials
1,802,555 Total Patients Enrolled
Bouthaina S DabajaPrincipal InvestigatorM.D. Anderson Cancer Center
5 Previous Clinical Trials
315 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have serious heart problems that need ongoing treatment.I do not have any active infections needing treatment.I've had radiation to the same area where my current cancer is, and can't have more without risking harm.I have an active hepatitis B or C infection.I am currently using alternative or complementary medicines.I have been newly diagnosed with early-stage follicular lymphoma, confirmed to be grade 1 or 2.My doctor decides if I need lamivudine to prevent hepatitis B.
Research Study Groups:
This trial has the following groups:- Group 1: Arm I (radiation therapy and rituximab)
- Group 2: Arm II (radiation therapy and observation)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger